These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 21640146)
1. APN/CD13-targeting as a strategy to alter the tumor accumulation of liposomes. Dunne M; Zheng J; Rosenblat J; Jaffray DA; Allen C J Control Release; 2011 Sep; 154(3):298-305. PubMed ID: 21640146 [TBL] [Abstract][Full Text] [Related]
2. Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects. Garde SV; Forté AJ; Ge M; Lepekhin EA; Panchal CJ; Rabbani SA; Wu JJ Anticancer Drugs; 2007 Nov; 18(10):1189-200. PubMed ID: 17893520 [TBL] [Abstract][Full Text] [Related]
3. Size-controlled, dual-ligand modified liposomes that target the tumor vasculature show promise for use in drug-resistant cancer therapy. Takara K; Hatakeyama H; Kibria G; Ohga N; Hida K; Harashima H J Control Release; 2012 Aug; 162(1):225-32. PubMed ID: 22728515 [TBL] [Abstract][Full Text] [Related]
4. Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. Curnis F; Arrigoni G; Sacchi A; Fischetti L; Arap W; Pasqualini R; Corti A Cancer Res; 2002 Feb; 62(3):867-74. PubMed ID: 11830545 [TBL] [Abstract][Full Text] [Related]
5. 68Ga-DOTA-NGR as a novel molecular probe for APN-positive tumor imaging using MicroPET. Zhang J; Lu X; Wan N; Hua Z; Wang Z; Huang H; Yang M; Wang F Nucl Med Biol; 2014 Mar; 41(3):268-75. PubMed ID: 24438818 [TBL] [Abstract][Full Text] [Related]
6. In vivo NIRF imaging-guided delivery of a novel NGR-VEGI fusion protein for targeting tumor vasculature. Ma W; Li G; Wang J; Yang W; Zhang Y; Conti PS; Chen K Amino Acids; 2014 Dec; 46(12):2721-32. PubMed ID: 25182731 [TBL] [Abstract][Full Text] [Related]
7. Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma. Loi M; Marchiò S; Becherini P; Di Paolo D; Soster M; Curnis F; Brignole C; Pagnan G; Perri P; Caffa I; Longhi R; Nico B; Bussolino F; Gambini C; Ribatti D; Cilli M; Arap W; Pasqualini R; Allen TM; Corti A; Ponzoni M; Pastorino F J Control Release; 2010 Jul; 145(1):66-73. PubMed ID: 20346382 [TBL] [Abstract][Full Text] [Related]
8. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Pastorino F; Brignole C; Marimpietri D; Cilli M; Gambini C; Ribatti D; Longhi R; Allen TM; Corti A; Ponzoni M Cancer Res; 2003 Nov; 63(21):7400-9. PubMed ID: 14612539 [TBL] [Abstract][Full Text] [Related]
9. Design of a dual-ligand system using a specific ligand and cell penetrating peptide, resulting in a synergistic effect on selectivity and cellular uptake. Takara K; Hatakeyama H; Ohga N; Hida K; Harashima H Int J Pharm; 2010 Aug; 396(1-2):143-8. PubMed ID: 20457236 [TBL] [Abstract][Full Text] [Related]
10. 13F-1, a novel 5-fluorouracil prodrug containing an Asn-Gly-Arg (NO2) COOCH3 tripeptide, inhibits human colonic carcinoma growth by targeting Aminopeptidase N (APN/CD13). Cui SX; Zhang HL; Xu WF; Qu XJ Eur J Pharmacol; 2014 Jul; 734():50-9. PubMed ID: 24726845 [TBL] [Abstract][Full Text] [Related]
11. Synthesis and evaluation of 64Cu-labeled monomeric and dimeric NGR peptides for MicroPET imaging of CD13 receptor expression. Chen K; Ma W; Li G; Wang J; Yang W; Yap LP; Hughes LD; Park R; Conti PS Mol Pharm; 2013 Jan; 10(1):417-27. PubMed ID: 23190134 [TBL] [Abstract][Full Text] [Related]
12. In vivo imaging of Aminopeptidase N (CD13) receptors in experimental renal tumors using the novel radiotracer (68)Ga-NOTA-c(NGR). Máté G; Kertész I; Enyedi KN; Mező G; Angyal J; Vasas N; Kis A; Szabó É; Emri M; Bíró T; Galuska L; Trencsényi G Eur J Pharm Sci; 2015 Mar; 69():61-71. PubMed ID: 25592229 [TBL] [Abstract][Full Text] [Related]
13. Tumor vascular targeting with tumor necrosis factor alpha and chemotherapeutic drugs. Corti A; Ponzoni M Ann N Y Acad Sci; 2004 Dec; 1028():104-12. PubMed ID: 15650236 [TBL] [Abstract][Full Text] [Related]
14. Anti-tumor and anti-angiogenic effect of metronomic cyclic NGR-modified liposomes containing paclitaxel. Luo LM; Huang Y; Zhao BX; Zhao X; Duan Y; Du R; Yu KF; Song P; Zhao Y; Zhang X; Zhang Q Biomaterials; 2013 Jan; 34(4):1102-14. PubMed ID: 23127332 [TBL] [Abstract][Full Text] [Related]
15. NGR-modified micelles enhance their interaction with CD13-overexpressing tumor and endothelial cells. Wang X; Wang Y; Chen X; Wang J; Zhang X; Zhang Q J Control Release; 2009 Oct; 139(1):56-62. PubMed ID: 19470394 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of 99mTc-probestin for imaging APN expressing tumors by SPECT. Pathuri G; Hedrick AF; Awasthi V; Ihnat MA; Gali H Bioorg Med Chem Lett; 2013 Sep; 23(18):5049-52. PubMed ID: 23937983 [TBL] [Abstract][Full Text] [Related]
18. Dual-modified liposomes with a two-photon-sensitive cell penetrating peptide and NGR ligand for siRNA targeting delivery. Yang Y; Yang Y; Xie X; Wang Z; Gong W; Zhang H; Li Y; Yu F; Li Z; Mei X Biomaterials; 2015 Apr; 48():84-96. PubMed ID: 25701034 [TBL] [Abstract][Full Text] [Related]
19. NGR peptide ligands for targeting CD13/APN identified through peptide array screening resemble fibronectin sequences. Soudy R; Ahmed S; Kaur K ACS Comb Sci; 2012 Nov; 14(11):590-9. PubMed ID: 23030271 [TBL] [Abstract][Full Text] [Related]